Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Thorax. 2021 Jun 10;77(1):22–30. doi: 10.1136/thoraxjnl-2020-216613

Figure 1. Flow diagram.

Figure 1.

a Less than the 745-patient sample size of SAILS due to 2 sites not participating in this study and a temporary cessation of recruitment into this study due to funding-related issues.

b Details of the number of patients who underwent assessments for each of the outcomes are reported in Tables 3 and 4. One patient at each of 6- and 12-month follow-up periods did not complete all of the outcome measures and hence, they were excluded from the sample size reported in the manuscript and the data in Tables 3 and 4.

c Four of 5 patients missed were alive at 6 months, one missed patient in the hyper-inflammatory subphenotype had unknown mortality status at 6 months.

d Eight eligible patients were not eligible for follow-up due to temporary cessation of recruitment (due to funding-related issues) for many of the study sites.

e Ten of 10 patients and 6 of 7 patients were alive in the hypo- and hyper-inflammatory subphenotypes, respectively. One patient in the hyper-inflammatory subphenotype was censored for survival analysis.